A small proportion of veterans who went from a metered-dose inhaler to a dry-powder inhaler had to revert to the metered-dose ...

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

GlaxoSmithKline (GSK) has announced full results from the Salford Lung Study (SLS), a pioneering study of COPD treatment aimed ... the likes of Novartis and AstraZeneca. Novartis yesterday ...

Starting with the Brestri Aerosphere COPD inhaler (pending regulatory approval), AstraZeneca intends to transition all of its MDIs to this technology by 2030. “The work we are doing with ...

Medicare Part D and Medicare Advantage (Part C) plans with drug coverage typically cover inhalers for COPD. But you may still be responsible for a portion of the cost. If you have chronic ...

Inhalers for COPD provide steroids, bronchodilators, or combination drugs. The three types differ in the mechanism by which the medication is inhaled and have different instructions for use.

For surgeons already split on their preference of inhaled pulmonary vasodilator to prevent postoperative right ventricular ...

AstraZeneca (NASDAQ:AZN) is one of the biggest players in the healthcare sector, whose medicines save the lives of tens of thousands of people every year. In this article, I will share six reasons ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...